TY - JOUR AU - Takigawa, Nagio AU - Ochi, Nobuaki AU - Yamane, Hiromichi PY - 2018 TI - Histology versus cytology: PD-L1 testing in non-small cell lung cancer JF - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research<sup>1</sup> Y2 - 2018 KW - N2 - Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab have been developed to treat malignant tumors, including non-small cell lung cancer (NSCLC). ICIs inhibit programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling between tumor cells expressing PD-L1 and cytotoxic T lymphocytes expressing PD-1. UR - https://tlcr.amegroups.org/article/view/23599